A5008917524- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Pneumonia and Respiratory Infections
- Bacterial Infections and Vaccines
- Monoclonal and Polyclonal Antibodies Research
- Renal cell carcinoma treatment
- Immune Cell Function and Interaction
- Neuroblastoma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Antimicrobial agents and applications
- T-cell and B-cell Immunology
- Streptococcal Infections and Treatments
- Bacterial biofilms and quorum sensing
- Antimicrobial Peptides and Activities
Sanquin
2021-2024
Amsterdam University Medical Centers
2021-2024
Oncode Institute
2021-2024
University of Amsterdam
2021-2024
University Medical Center Utrecht
2020-2023
Utrecht University
2022-2023
High-risk pediatric neuroblastoma patients have a dismal survival rate despite intensive treatment regimens. New options are thus required. Even though HLA expression in is low and immune cell infiltrates limited, the presence of tumor infiltrating lymphocytes (TILs) indicative for better patient survival. Here, we show that most lesions contain viable after induction chemotherapy, with high percentages CD3+ T cells. We therefore expanded TILs tested their anti-tumoral activity. With...
is the leading cause of community-acquired pneumonia and an important childhood mortality. Despite introduction successful vaccines, global spread both non-vaccine serotypes antibiotic-resistant strains reinforces development alternative therapies against this pathogen. One possible route monoclonal antibodies (mAbs) that induce killing bacteria via immune system. Here, we investigate whether mAbs can be used to pneumococcal for which current vaccines show unsuccessful protection. Our study...
Metastatic renal cell carcinoma (RCC) has a poor prognosis. Recent advances have shown beneficial responses to immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies. As only subset of RCC patients respond, alternative strategies should be explored. Patients refractory anti-PD-1 therapy may benefit from autologous tumor-infiltrating lymphocyte (TIL) therapy. Even though efficient TIL expansion was reported lesions, it is not well established how many products are tumor-reactive,...
Abstract Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and an important childhood mortality. Despite introduction successful vaccines, global spread both non-vaccine serotypes antibiotic-resistant strains reinforce development alternative therapies against this pathogen. One possible route monoclonal antibodies (mAbs) that induce killing bacteria via immune system. Here we investigate whether mAbs can be used to pneumococcal for which current vaccines show...
Abstract Adoptive transfer of tumor infiltrating lymphocytes (TIL therapy) has shown great potential for the treatment solid cancers, including non-small cell lung cancer (NSCLC). However, not all patients benefit from this therapy, and parameters that define likelihood TIL products to be reactive are date unknown. Defining prognostic markers correlate with high level tumor-reactivity is key achieving better tailored immunotherapies. To determine whether composition immune infiltrates...
Adoptive transfer of tumor infiltrating lymphocytes (TIL therapy) has proven highly effective for treating solid cancers, including non-small cell lung cancer (NSCLC). However, not all patients benefit from this therapy yet unknown reasons. Defining markers that correlate with high tumor-reactivity the autologous TIL products is thus key achieving better tailored immunotherapies. We questioned whether composition immune infiltrates correlated expanded products. Unbiased flow cytometry...
Abstract Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Because current treatment regimens show limited success rates, alternative therapeutic approaches are needed. We recently showed that treatment-naive, stage I/II primary NSCLC tumors contain a high percentage tumor-reactive T cells, and these cells can be effectively expanded used for generation autologous TIL therapy. Whether promising findings also hold true metastatic lesions unknown...